Patients who face an increased risk of passing a genetic disease to their offspring have now an option to have this risk significantly reduced. Invicta’s research team had developed a new method of testing embryonic genetic material – PGS/PGD NGS. It implements an innovative technique of the next generation DNA sequencing, that has previously been used to analyze the samples from adult patients. PGS/PGD NGS is a solution for couples who are worried about genetic disease occurrence in their offspring due to hereditary genetic conditions or advanced reproductive age.
We wanted to take advantage of the latest methods of genomic analysis to test the material from the embryos. Every year we see many couples whose babies were born sick or died shortly after birth because of genetic defects. Until now we have been using other techniques used worldwide, but none of them gave us opportunities comparable to PGD NGS – said prof. Krzysztof Lukaszuk, Medical Director of INVICTA Infertility Clinics.
Next-generation DNA sequencing (NGS) is an innovative solution enabling detailed examination of the human genome. Currently, it is a reference method (used to confirm results) for other techniques used for the genetic diagnosis, such as microarrays (used to examine the chromosomes) and FISH (process using fluorescence microscopy and used to study large genetic defects). NGS is an extremely sensitive method, allowing for the identification of even the smallest changes.